To cause disease, bacterial pathogens must first breach physical barriers, such as the mucous membrane that lines organs, and then successfully replicate and disseminate while avoiding destruction by the immune system. Many bacterial pathogens accomplish this by secreting proteins into their host environment, which act to subvert or dampen the expanding immune response. Here, we discuss how bacterial pathogens use an arsenal of secreted virulence proteins to modify the outcome of innate immune activation by altering how the immune system recognizes microbial invaders.
Introduction
Bacterial pathogens have evolved highly sophisticated mechanisms to adapt to their host environment in order to promote successful replication and dissemination. Bacterial subsistence in the context of the host environment involves a complex interplay between bacterial survival strategies and the ensuing host response to infection, which in many cases serves to limit the replication of the microorganism and prevent its dissemination within the body and to new hosts. The host response to infection begins with the identification of a foreign invader through the use of innate immune surveillance systems, which alert the body to an infection and induce a suite of inflammatory molecules that ultimately shape the adaptive arm of the immune response. The importance of this central defense mechanism -called innate immunity -is exemplified by its presence in organisms across all kingdoms, including insects, nematodes, plants, and in more complex mammals where it serves as the front-line defense against microorganisms before the adaptive immune response is initiated [1, 2] .
The ability to detect, respond to, and destroy invading microbes is a central tenet for survival, and thus forms a formidable barrier that successful pathogens must overcome [3, 4] . This is especially true of infecting microbes that rapidly replicate and induce disease symptoms that overwhelm the innate defenses of the host and transmit to a new host before the adaptive immune response can be activated, but is also necessary for 'stealth' pathogens that replicate more slowly and cause persistent infections by interfering with both innate and adaptive immune pathways [5] . The innate arm of the immune response is vigorous and intuitive, responding to molecular signatures characteristic of many pathogens, as opposed to unique antigens that ultimately shape the exquisite specificity and clonal nature of adaptive immunity.
In order to persist within and exploit their chosen host in the face of a robust innate immune response, bacterial pathogens often secrete virulence factors (or effectors) into host cells or into the surrounding space that in some way modify host biology to the benefit of the pathogen. The host cell targets of secreted bacterial proteins are diverse, including cytoskeletal components, host cell receptors, an array of signaling molecules, and other host proteins compartmentalized in various organelles. Intense research into this area is beginning to elucidate the repertoire of effector targets, although the mechanism of their action is often more elusive. The modification of host cell pathways allows incoming microbes to replicate in a desired niche in the body, quite often inside host cells, or sometimes on the surface of a host cell. This is the first step in bacterial colonization and pathogenic microbes must still overcome a large hurdle in order to be successful -surviving, replicating and disseminating in the face of host immunity.
In this review, we discuss how pathogenic bacteria utilize secreted proteins to avoid recognition by the innate immune system of the host and how, if recognized, similar secreted proteins function to subvert or dampen the expanding immune response. We have emphasized the use of type III and type IV secretion pathways because these secretion systems provide direct conduits into the host cell where the translocated effectors can directly modify immune effector functions. We also examine innate immune pathways for which little information is currently known and which could be potential targets of translocated bacterial virulence factors.
Innate Immunity and the Weapons to Fight It
There are several strategies that microbes employ to circumvent and overcome innate responses. Many bacterial pathogens have evolved sophisticated secretion systems to inject bacterial molecules into animal and plant cells. These type III and type IV secretion systems [6] [7] [8] [9] [10] are complex organelles that span the Gram-negative envelope, and form a conduit to deliver proteins (and, in the case of type IV systems, DNA) into host cells. The general components of type III and type IV secretion systems are usually conserved, but the particular translocated effectors that enter into host cells are often unique to particular pathogens. The repertoire of effectors dictates the choice of host, how the pathogen behaves inside that host, and ultimately the disease. Many, but certainly not all, effectors are key virulence factors, that is, they are required to cause disease. These effectors target host cellular processes including those linked to innate responses, disrupting or altering these pathways as part of the disease process. The cellular targets are numerous, although those of choice are often central regulators of essential processes, such as cytoskeletal dynamics and vesicular trafficking. Although currently the number of examples is limited, it is possible that for most central cellular processes there is at least one microbial pathogen that targets it. In addition to the type III and IV systems, at least three other secretion systems exist, including type I (signalsequence-independent pathway), type II (the terminal step of a two-step secretion process) and type V (autotransporter pathway) that serve to move various protein substrates from inside bacteria to the extracellular space (reviewed in [11] [12] [13] [14] ).
Picking a Niche and Sticking to It
Phagocytosis is an important innate defense mechanism, a central event where innate and adaptive immunity converge. Phagocytosis allows the internalization and destruction of many pathogens by immune cells, and is the essential prerequisite to processing and presentation of microbial antigens for generation of a specific, adaptive immune response [15] . Crucial to these functions are phagocytic cells, or more specifically professional antigen-presenting cells (APCs) such as dendritic cells and macrophages. These APCs are situated in peripheral and lymphoid tissues and are able to recognize structural motifs and nucleic acids that are conserved in micro-organisms but are not present in higher eukaryotes. These motifs are referred to as pathogen-associated molecular patterns (PAMPs; see more below), the binding of which to their corresponding pattern recognition receptors (PRRs) leads to a cascade of signaling events promoting the activation of innate and adaptive immune responses [16] . Bacterial pathogens have evolved strategies for dealing with the activities of phagocytes, some by preventing uptake into these cells, and others by actively invading APCs and establishing intracellular residency.
The Outsider Strategy
Some bacterial pathogens use highly effective mechanisms to avoid phagocytic uptake into macrophages, thereby avoiding robust microbicidal effector functions [3] . For some bacterial pathogens such as Yersinia sp., enteropathogenic Escherichia coli, and Pseudomonas aeruginosa, this process of 'antiphagocytosis' is elicited by their type III secretion system, which delivers bacterial proteins into the macrophage cytosol to specifically impair the signaling downstream of phagocytic receptors (Figure 1 ). Enteropathogenic E. coli inhibits phagocytosis into macrophages by attenuating phosphatidylinositol (PI) 3-kinase activation shortly after bacterial contact with the host cell surface [17] . This process occurs in wild-type bacteria, but not in type III secretion mutants, although the identity of the type III effector(s) responsible for this activity remains to be identified. P. aeruginosa secretes at least two exotoxins called ExoS [18] and ExoT [19, 20] through its type III secretion system. These proteins have GTPase-activating activity towards Rho-family GTPases, such as Rho, Rac1 and Cdc42, and this prevents P. aeruginosa uptake by both epithelial cells and macrophages.
Yersinia use a more functionally overlapping set of type-III-secreted virulence proteins to interfere with phagocytosis, with at least three secreted effectors It would seem feasible that TLR-dampening activities might be exploited by bacterial pathogens to diminish TLR signaling. However, because virulence proteins that mimic eukaryotic ones often arise by convergent evolution, finding bacterial homologues (at the nucleotide or amino acid level) of negative regulators of TLR signaling might be difficult. Instead, identifying a functionally equivalent bacterial protein that can antagonize the signaling cascade downstream of TLR and IRAK might be better accomplished through genetic and proteomic screens looking for bacterial proteins that interact directly with these surveillance receptors and their associated signaling molecules.
Many of the PAMPs that stimulate TLR signaling have been elucidated, including lipopolysaccharide (LPS), which is specific for TLR4, bacterial flagellin (TLR5), CpG DNA (TLR9) and lipoteichoic acid (TLR2) found predominantly in the cell wall of Gram-positive bacteria. In the case of TLR4, it has been noted that lipid A, the pro-inflammatory component of bacterial LPS, varies in its acylation state and that this can alter how TLR4 responds to LPS. Miller and co-workers have shown that both P. aeruginosa [55] and Salmonella enterica serovar Typhimurium [56] modify their lipid A acylation state, thereby changing the stimulatory activity of this lipid in response to recognition by TLR4. For instance, deacylation of lipid A by Salmonella in response to the host environment decreases its ability to induce TLR4-mediated NF-κ κB activation [56] , whereas conversion of penta-acylated lipid A in P. aeruginosa to hexa-acylated lipid A makes the LPS more inflammatory [57] . The generation of a more stimulatory LPS in P. aeruginosa appears to be partially offset by the ability of hexa-acylated lipid A to resist damage by cationic antimicrobial peptides [55] . Although this mechanism of immune system avoidance does not rely specifically on proteins secreted from the bacteria, it is an important avoidance mechanism that acts in concert with other secreted effector proteins whose collaborative effect is to ensure host adaptation aimed at avoiding recognition by the immune system. The recent discovery that phagosome maturation in macrophages is regulated, in part, by TLR4-dependent signals [58] and that eliminating TLR-based signals impairs phagocytosis of various pathogens makes it possible that several of the pathogens that block their phagocytic uptake by macrophages may do so by inhibiting an essential TLR-dependent pathway. Current Biology NF-κB domain (or CARD) and multiple carboxy-terminal leucine-rich repeats that mediate responsiveness to bacterial peptidoglycan [70] . Recent work has identified the moieties present in peptidoglycan that are recognized by NOD1 and NOD2 -NOD2 recognizes a conserved muramyldipeptide moiety present in the cell wall of essentially all bacteria [71, 72] , whereas NOD1 appears to confer greater specificity for detection of diaminopimelic acid present in the cell wall peptidoglycan of Gram-negative bacteria [73, 74] .
Bacterial Hijacking of TLRs Can Manipulate the Downstream Response
Similar to TLR, the functional importance of NOD signaling has been strengthened by the identification of patients with nod mutations who are more susceptible to chronic diseases with a bacterial etiology. In a seminal paper, nod2 was described as the first susceptibility gene involved in the pathology of Crohn's disease [75] : a disease-associated frame-shift mutation in the LRR domain of nod2 resulted in a NOD2 protein that no longer recognized peptidoglycan. At present, bacterial proteins that antagonize the signaling cascades directly proximal to NOD proteins have not been described. However, modifying or dampening NOD-dependent signaling pathways might allow intracellular pathogens a stealthy entry into host cells, allowing them to evade detection and minimize the pro-inflammatory reactions that would alert the immune system to their presence. Members of the Chlamydia species might even have adapted ways to avoid NOD-based signaling altogether. For instance, the 'chlamydial anomaly' is based on the observed paradox that chlamydiae are sensitive to antibiotics that inhibit peptidoglycan synthesis (like penicillin), yet the organisms themselves do not make detectable levels of peptidoglycan. This is further confounded by the presence in the chlamydial genome of genes that apparently encode products of the peptidoglycan synthesis machinery. Could chlamydiae have evolved to produce a modified peptidoglycan-like structure that is not recognized by NODs? It is possible that NOD receptors could be utilized as sensitive intracellular detectors of peptidoglycan to sort out the chlamydial anomaly, which is currently unresolved.
Recent data have shed light on the components downstream of NOD proteins that contribute to inflammatory signaling cascades. For example, upon infection of HEK293 cells with Streptococcus pneumoniae it was demonstrated that NOD2 is required for the downstream activation of NF-κ κB [76]
. Interestingly, by using dominant-negative constructs and small inhibitory RNA, it was shown that the IL-1 receptorassociated kinase 2 (IRAK2) was involved in NOD2-dependent activation of NF-κ κB in response to pneumococcal infection. This result is intriguing because it represents the first report linking the membrane-proximal IRAK family of kinases (associated with TLR-dependent signaling) with the NOD signaling pathway. Also in human colonic epithelial cells that are poorly responsive to LPS, it has been shown that constitutive expression of NOD1 plays an important role in recognizing several enteric pathogens that would normally bypass TLR signaling in the infected epithelium [77] . Together these studies allude to a functional interplay between TLR and NOD, which has not yet been extensively investigated. Given that secreted bacterial factors have been identified that modulate TLR signaling cascades, the identification of secreted virulence factors of intracellular organisms that directly antagonize the function of NOD proteins seems likely.
Targeting the Converging Signals from TLRs and NODs
As mentioned above, one of the common targets of both TLR and NOD signaling is the pro-inflammatory transcription factor NF-κ κB. Activation and nuclear translocation of NF-κ κB in response to surveillance signaling is necessary for the production of an appropriate inflammatory response [78] . 
Abating the Signals Governing Adaptive Immunity
Some of the more extensively adapted of the human pathogens are grouped within the chlamydiae, which have caused human diseases since antiquityancient Egyptian medical papyri point to the existence of Chlamydia trachomatis infections. Chlamydiae are obligate intracellular pathogens meaning that, akin to viruses, invasion of a susceptible host cell is a prerequisite to initiation of their developmental cycle. As obligate intracellular pathogens, chlamydiae are exquisitely adapted for exploitation of their hosts, which include both warm-blooded mammals and several reptilian and amphibian species. In humans, they give rise to the most prevalent bacterial sexually transmitted disease and are the leading cause of blindness in endemic areas of the world [84] .
As with most intracellular infections, the cellular immune response to Chlamydia infection is based on antigen-specific major histocompatibility (MHC) class I-restricted CD8 + cytotoxic T lymphocytes (CTLs) that recognize and kill cells infected with bacteria. Indeed, there are at least two reports demonstrating recognition by protective CD8 + CTLs of inclusion membraneassociated proteins from C. trachomatis [85, 86] , indicating that at least some chlamydial antigens are recognized in the cytosol and are processed into peptides for loading of MHC class I molecules. However, the chronic nature of the diseases associated with these organisms alludes to a mechanism involving a modulation of the upstream pathways governing the transition from innate to adaptive immunity. Interestingly, Zhong and colleagues demonstrated the ability of both C. trachomatis [87] and C. pneumoniae [88] to degrade a host molecule called RFX5, a transcription factor involved in the upstream activation of MHC class I expression. This proteolytic activity was dependent on a chlamydial protein, which they called CPAF (for chlamydial protease-like activity factor), a 70 kDa heterodimeric protein secreted into the cytoplasm of infected host cells. RFX5 degradation was inhibited by lactacystin, an irreversible proteasome inhibitor, and by depletion of CPAF with specific antibodies. In addition, this same group has demonstrated the ability of the CPAF protease to interfere with MHC class II expression on the surface of infected cells [89] . Chlamydial inhibition of MHC class II expression involved degradation of upstream stimulatory factor 1 (USF-1), a constitutively expressed transcription factor required for expression of class II transactivator (CIITA), which is in turn required for IFN-γ γ-inducible MHC class II expression.
Because these experiments were carried out in epithelial cell lines, it would be germane to study the ability of chlamydiae to inhibit surface expression of MHC class I and II molecules in professional APCs, as it is these cells that would ultimately prime a naïve immune system to the infection. While it has yet to be determined just how CPAF is introduced into the cytoplasm of infected host cells, it was demonstrated to be exclusively cytoplasmic in infected host cells and not present in purified chlamydial organisms. It is possible that CPAF is a type-III-secreted substrate, translocated directly into the cytoplasm across the inclusion membrane, since these pathogens have the core genetic components to assemble a type III secretion system. With the use of heterologous bacterial systems with tractable genetics, determining whether CPAF is a type III substrate should be achievable.
Helicobacter pylori is another human pathogen that modulates the transition from innate to adaptive immune responses. H. pylori is primarily an extracellular pathogen that colonizes the human gastric Other circumstantial evidence exists that secreted bacterial proteins from Salmonella might be involved in downregulating microbicidal peptide production in Paneth cells in mouse intestine. It was reported that oral inoculation of mice with wild-type Salmonella enterica serovar Typhimurium decreased the expression of cryptdins (the mouse counterpart of human α α-defensins), while a Salmonella mutant defective for the type III secretion of Salmonella pathogenicity island-1 virulence factors lacked this inhibitory activity [102] . Perhaps more directly, others have demonstrated that staphylokinase, a proteolytic exotoxin produced and secreted by Staphylococcus aureus, induced the extracellular release of α α-defensins from polymorphonuclear cells, yet was then able to form a direct complex with these peptides to completely neutralize their microbicidal activity [103] . It remains to be seen to what degree these aforementioned strategies for dealing with cationic peptides actually contribute to the pathogenesis of these organisms during a natural infection. However, it seems that at least some microbes have made antimicrobial peptides a target of their 'anti-immunity' arsenal.
Moderating the Function of the Host Proteasome
The eukaryotic proteasome performs many physiological roles inside cells, such as regulation of the cell cycle, processing of certain transcription factors, and controlling protein turnover. With reference to the immune system, the proteasome is responsible for the degradation of microbial proteins and is the main provider of peptide antigens for MHC class I presentation (Figure 3) . Of relevance, it has been shown that direct interaction with model colonic epithelia by nonpathogenic Salmonella attenuates NF-κ κB-dependent synthesis of inflammatory cytokines (namely IL-8) normally elicited by pro-inflammatory stimuli [104] . These authors demonstrated that mucosal tolerance to nonpathogenic enteric bacteria was mediated by an inhibition of Iκ κB degradation, which prevented nuclear translocation of NF-κ κB. Although Iκ κB was phosphorylated in response to intestinal microflora, polyubiquitination of Iκ κB did not occur, and thus it was not a substrate for the 26S proteasome. The authors suggested that the ability of the bacteria-epithelial cell interaction to induce an anti-inflammatory response might be due to the delivery of a secreted bacterial factor that either reduces the activity of the Iκ κB ubiquitin ligase directly or increases a specific de-ubiquitinating activity.
Brumell and co-workers [105] have also demonstrated a relationship between bacterial pathogens in the cytosol of macrophages and the ubiquitin-proteasome system. In this work, Salmonella enterica serovar Typhimurium that escaped invasion vacuoles were polyubiquitinated in the cytosol and their growth was constrained by recruitment of the proteasome to the bacterial surface. Cytosolic growth restriction occurred in macrophage cell lines, but not in epithelial cells, suggesting that the cytosol of certain cell types is differentially permissive for bacterial growth [106] . In support of this observation is the finding that a Salmonella enterica serovar Typhimurium mutant that lacks the type-III-secreted effector SifA is unable to stabilize the bacterial vacuole and is consequently released into the cytosol of infected host cells. Subsequently, the cytosolic bacteria are able to replicate to at least wild-type levels in epithelial cells [107] but are growth-restricted in macrophages [108] . It is possible that certain APCs have developed alternative mechanisms of cytosolic surveillance involving the ubiquitin-proteasome system that would put pressure on intracellular pathogenic bacteria that escape into the cytosol. Indeed, chemical inhibition of the proteasome promoted the cytosolic replication of Salmonella in macrophages, where it was normally growthrestricted [105] . However, it is not known whether the use of proteasome inhibitors might affect other host cell functions related to antimicrobial effector function.
Could some bacterial pathogens secrete virulence factors into the host macrophage that interfere or modify ubiquitination and proteasome activity directly? Based on the work of Neish et al.
[104] discussed above, this hypothesis seems highly probable. Such a strategy might give intravacuolar bacteria that escape into the cytosol a chance to breach the host cell and gain access to the extracellular space. It might also have the added advantage of limiting NF-κ κB activation and inflammatory reactions that also require proteasome activity.
Uropathogenic and meningitis-causing E. coli use a different mechanism to exploit the function of the proteasome by secreting a toxin called cytotoxic necrotizing factor 1 (CNF1). CNF1 specifically deamidates a glutamine residue in RhoA, Rac and Cdc42 into a glutamic acid, which abrogates the GTPase activity of these proteins and renders them constitutively active [109, 110] . Paradoxically, CNF1-mediated activation of these GTPases promotes their ubiquitination and degradation by the proteasome [111] . This cycling of GTPase activation followed by degradation of the activated Rho proteins helps to confer a highly invasive phenotype to uropathogenic E. coli. Also, because the activation of Rho-family GTPases can induce an intrinsic host defense program, it has been suggested that ubiquitin-mediated proteasomal degradation of activated Rho proteins in response to CNF1 intoxication may restrict the magnitude of the host immune response seen during infection with uropathogenic and meningitis-causing E. coli [112] . This is an intriguing example of how a secreted bacterial virulence factor achieves both invasion and immune dampening by indirectly commandeering the host cell proteasomal machinery. Although currently there are no reports describing secreted bacterial effectors that directly modulate the activity of the proteasome, the idea that this system may somehow constitute an innate surveillance system that bacterial pathogens might usurp is a provocative hypothesis -one that has been substantiated already for various viral pathogens [113, 114] .
Perspectives
Within the past decade, there has been remarkable progress made in our understanding of both innate responses and bacterial effectors. The recent convergence of these fields has resulted in a rapidly expanding knowledge of these processes, and more importantly, disease mechanisms. It has forced microbiologists to learn cell biology and immunology, and immunologists to appreciate the breadth and strategies of microbial pathogens. It is also providing a plethora of molecules that can be used as tools to further probe innate response mechanisms. The number of recently discovered bacterial effectors is increasing very rapidly, and the task of identifying host cellular targets lags significantly. Within the next few years, as knowledge in both fields continues to expand, our knowledge of how pathogens exploit innate responses will grow tremendously. More importantly, this information can be applied to understanding microbial diseases. The ability to modulate innate responses to overcome pathogens to treat microbial infections is a very attractive concept [115] . However, given that microbes are genetically very promiscuous and constantly exchanging virulence factors, it is likely that they will continue to evolve new combinations of virulence factors to bypass innate responses, resulting in new emerging infectious diseases. Understanding the complex interactions that occur between microbial pathogens and their hosts that result in disease remains a lofty goal of cellular microbiology. It is hoped we will eventually understand enough to develop new therapies to counter these microbial threats.
